Skip to content
value.today

Response Biomedical Corp.

Total raised
$20 M
4 rounds on record
Latest round
$3 M
Sep 2013
First round on record
May 2009
Today
Private
No later event on record

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Response Biomedical Corp.
MonthRaisedRaiseSizeInvestorsSoldFiling
Sep 2013$3 MNo. 4$2 to $10 million

Response Biomedical Corp.: Raise no. 4, Sep 2013

Investors in this round

10 investors had bought by the notice of Oct 15, 2013: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $4 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(c): may be advertised publicly; every buyer must be a verified accredited investor
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$74,295
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in British Columbia, Canada

People named in the notice

  • Jeffrey L. Purvin · Executive Officer, Director
  • William J. Adams · Executive Officer
  • Anthony F. Holler · Director
  • Clinton H. Severson · Director
  • David A. Wang · Director
  • Joseph D. Keegan · Director
  • Lewis H. Shuster · Director
  • Peter A. Thompson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On fees: “Cash Commission: $30,957; Warrant Commission*: $43,338. *17,689 warrants to purchase common shares @$2.45 per share. Amounts listed are in Canadian Dollars”
  • On the amounts: “Amounts listed are in Canadian dollars”

Signed by William J. Adams, Cfo. Source: SEC Form D, newest notice filed Oct 15, 2013. Read the notice at the SEC.

equity, optionsSEC
Dec 2011$5 MNo. 3$2 to $10 million

Response Biomedical Corp.: Raise no. 3, Dec 2011

Investors in this round

7 investors had bought by the notice of Jan 6, 2012: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, other: Unit offering; a Unit is composed of 1 common share and 1 common share purchase warrant.
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in British Columbia, Canada

People named in the notice

  • Anastasios A. Tsonis · Executive Officer
  • Dr. Peter A. Thompson · Executive Officer, Director
  • Clint J. Severson · Director
  • Dr. Anthony F. Holler · Director
  • Dr. David J. Wang · Director
  • Dr. Joseph D. Keegan · Director
  • Lewis J. Shuster · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Amounts reported in Item 13 are converted from Canadian Dollars using the Bank of Canada's Noon Exchange Rate on 12/30/2011 of CDN$1=US$0.9833.”

Signed by Anastasios Tsonis, Corporate Controller. Source: SEC Form D, newest notice filed Jan 6, 2012. Read the notice at the SEC.

equity, optionsSEC
Jul 2010$8 MNo. 2$2 to $10 million

Response Biomedical Corp.: Raise no. 2, Jul 2010

Investors in this round

3 investors had bought by the notice of Aug 12, 2010: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$8 M of $8 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
$5 million to $25 million
Sales commissions
none
Finders' fees
$231,750
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in British Columbia, Canada

People named in the notice

  • Duane A. Morris · Executive Officer
  • Livleen A. Kaler · Executive Officer
  • S. Wayne Kay · Executive Officer, Director
  • Anthony A. Holler · Director
  • Jonathan A. Wang · Director
  • Peter A. Thompson · Director
  • Richard A. Bastiani · Director
  • Richard A. Bear · Director
  • Todd A. Patrick · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Trout Capital LLC (CRD 131489) · New York, New YorkSold in NY

Signed by Livleen Kaler, VP, Finance & Administration and Chief Financial Officer. Source: SEC Form D, newest notice filed Aug 12, 2010. Read the notice at the SEC.

equitySEC
May 2009$4 MNo. 1$2 to $10 million

Response Biomedical Corp.: Raise no. 1, May 2009

Investors in this round

12 investors had bought by the notice of May 29, 2009: 12 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $7 M offered; $3 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them, other: Units = 1 common & 1/2 warrant for common @ Cdn$0.25 for 2 yrs
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
$5 million to $25 million
Sales commissions
$195,936
Finders' fees
none
Paid to its own people
$489,993 (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in A1

People named in the notice

  • Duane A. Morris · Executive Officer
  • Livleen Kaler · Executive Officer
  • Paul Harris · Executive Officer
  • S. Wayne Kay · Director, Executive Officer
  • Anthony F. Holler · Director
  • Ian A. Webb · Director
  • Richard J. Bastiani · Director
  • Richard K. Bear · Director
  • Todd R. Patrick · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Haywood Securities Inc. · broker-dealer Haywood Securities (USA) Inc. (CRD 42072) · Vancouver, A1Sold in no state named

Remarks in the notice

  • On fees: “Haywood also received 894,410 warrants @ Cdn$0.25 for 24 months”
  • On the amounts: “(c) represents maximum exercise price of warrants”
  • On the use of proceeds: “For payment of 2008 short-term incentives and 2008 board of director fees”

Signed by S. Wayne Kay, Chief Executive Officer. Source: SEC Form D, newest notice filed May 29, 2009. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Response Biomedical Corp. chose not to state its revenue in its newest notice of a funding round (Oct 2013).

    SEC Form D · Oct 2013

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Oct 2013

That is all the official record says: Response Biomedical Corp. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Response Biomedical Corp. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 12 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Response Biomedical Corp.
NameRoleNamed in
Jeffrey L. PurvinExecutive officerOct 2013
William J. AdamsExecutive officerOct 2013
Anastasios A. TsonisExecutive officerJan 2012
Dr. Peter A. ThompsonExecutive officerJan 2012
Duane A. MorrisExecutive officerAug 2010
Livleen A. KalerExecutive officerAug 2010
S. Wayne KayExecutive officerAug 2010
Livleen KalerExecutive officerMay 2009
Paul HarrisExecutive officerMay 2009
Anthony F. HollerDirectorOct 2013
Clinton H. SeversonDirectorOct 2013
David A. WangDirectorOct 2013
Jeffrey L. PurvinDirectorOct 2013
Joseph D. KeeganDirectorOct 2013
Lewis H. ShusterDirectorOct 2013
Peter A. ThompsonDirectorOct 2013
Clint J. SeversonDirectorJan 2012
Dr. Anthony F. HollerDirectorJan 2012
Dr. David J. WangDirectorJan 2012
Dr. Joseph D. KeeganDirectorJan 2012
Dr. Peter A. ThompsonDirectorJan 2012
Lewis J. ShusterDirectorJan 2012
Anthony A. HollerDirectorAug 2010
Jonathan A. WangDirectorAug 2010
Richard A. BastianiDirectorAug 2010
Richard A. BearDirectorAug 2010
S. Wayne KayDirectorAug 2010
Todd A. PatrickDirectorAug 2010
Ian A. WebbDirectorMay 2009
Richard J. BastianiDirectorMay 2009
Richard K. BearDirectorMay 2009
Todd R. PatrickDirectorMay 2009